Fusen Pharmaceutical Company Limited Provided group earnings guidance for the year ended 31 December 2023. The board of directors of the Company would like to inform the shareholders and potential investors that, based on the unaudited consolidated management accounts of the Group for the year ended 31 December 2023 (FY2023) and the information currently available to the Company, the Group is expected to record an expected loss attributable to owners of the Company with a range from approximately RMB35 million to RMB 43 million for FY2023, as compared with the loss attributable to owners of the Company of approximately RMB 34.6 million for the year ended 31 December 2022 (FY2022).